Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.
The results of the collaborative research, published today in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as age-related macular degeneration (AMD).
AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an ageing population.
A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.
This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.
Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.
The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.
Dr de Cogan said: “The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.
“Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments.
“The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.
“We believe this is going to be very important in terms of empowering of patients and reducing the cost of treatment to the NHS.”
Learn more: University of Birmingham develops revolutionary eye drops to treat age-related blindness
[osd_subscribe categories=’age-related-macular-degeneration’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “AGE-RELATED MACULAR DEGENERATION’]
The Latest on: Age-related macular degeneration
[google_news title=”” keyword=”age-related macular degeneration” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Over 50? Find out more about this age related eye problem with Stephen Olwell Opticians
Hi there, Stephen here again with some more information regarding your eyes and their health.Sorry it’s been so long. Last summer I wrote an article about sun exposure that seemed to catch the ...
- Cataract Surgery in Patients With Diabetes and Age-Related Macular Degeneration
The timing of surgery is critical as an unclear view of the retina may delay possible treatment for neovascular age-related macular degeneration (e.g., with photodynamic therapy). Patients should ...
- Age related macular degeneration: What to ask your doctor
We've tried to contact you several times as we haven't been able to take payment. You must update your payment details via My Account or by clicking update payment details to keep your ...
- Age-Related Macular Degeneration: Putting a Hole in Our World
Estimates show that by 2040, age-related macular degeneration may affect nearly 300 million people worldwide. And we are very limited in our ability to treat or prevent it. Here's what to know.
- Wet vs. Dry Age-Related Macular Degeneration (AMD)
In dry AMD, light-sensitive cells in the macula gradually break down, while in wet AMD, abnormal blood vessels start to grow beneath the retina.
via Google News and Bing News